EP3914620 - TREATMENT OF T CELL LYMPHOMA [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 30.03.2023 Database last updated on 24.08.2024 | |
Former | Request for examination was made Status updated on 29.10.2021 | ||
Former | The international publication has been made Status updated on 03.08.2020 | ||
Former | unknown Status updated on 03.02.2020 | Most recent event Tooltip | 29.01.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Innate Pharma 117, Avenue de Luminy 13009 Marseille / FR | [2021/48] | Inventor(s) | 01 /
ABDELAZIM, Hatem 538 Rue Paradis 13008 Marseille / FR | 02 /
PATUREL, Carine 411 Allée du Bois 69280 Marcy L'etoile / FR | [N/P] |
Former [2021/48] | 01 /
ABDELAZIM, Hatem 13008 Marseille / FR | ||
02 /
PATUREL, Carine 69280 Marcy L'etoile / FR | Representative(s) | Cabinet Becker et Associés 25, rue Louis le Grand 75002 Paris / FR | [N/P] |
Former [2021/48] | Völlmy, Lukas Innate Pharma IP Department 117, avenue de Luminy 13009 Marseille / FR | Application number, filing date | 20701559.5 | 20.01.2020 | [2021/48] | WO2020EP51234 | Priority number, date | US201962795194P | 22.01.2019 Original published format: US 201962795194 P | [2021/48] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020152081 | Date: | 30.07.2020 | Language: | EN | [2020/31] | Type: | A1 Application with search report | No.: | EP3914620 | Date: | 01.12.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 30.07.2020 takes the place of the publication of the European patent application. | [2021/48] | Search report(s) | International search report - published on: | EP | 30.07.2020 | Classification | IPC: | C07K16/28, A61K31/282, A61K31/7068, A61K39/395, A61P35/00, A61P35/02, G01N33/53 | [2021/48] | CPC: |
C07K16/2803 (EP,KR,US);
A61K39/3955 (KR);
A61K31/282 (EP,US);
A61K31/555 (EP,KR);
A61K31/7068 (EP,KR,US);
A61K33/243 (EP,KR);
A61K39/39558 (EP,US);
A61P35/00 (EP,US);
A61P35/02 (EP,KR);
G01N33/574 (KR);
G01N33/57426 (EP,US);
A61K2039/505 (EP,KR,US);
A61K2039/804 (EP);
A61K2300/00 (KR);
C07K2317/24 (EP,KR);
| C-Set: |
A61K31/282, A61K2300/00 (EP);
A61K31/555, A61K2300/00 (EP);
A61K31/7068, A61K2300/00 (EP);
A61K33/243, A61K2300/00 (EP); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/48] | Title | German: | BEHANDLUNG VON T-ZELL-LYMPHOMEN | [2021/48] | English: | TREATMENT OF T CELL LYMPHOMA | [2021/48] | French: | TRAITEMENT DU LYMPHOME À CELLULES T | [2021/48] | Entry into regional phase | 29.07.2021 | National basic fee paid | 29.07.2021 | Designation fee(s) paid | 29.07.2021 | Examination fee paid | Examination procedure | 29.07.2021 | Amendment by applicant (claims and/or description) | 29.07.2021 | Examination requested [2021/48] | 29.07.2021 | Date on which the examining division has become responsible | 29.03.2023 | Despatch of a communication from the examining division (Time limit: M04) | 05.05.2023 | Reply to a communication from the examining division | Fees paid | Renewal fee | 27.01.2022 | Renewal fee patent year 03 | 27.01.2023 | Renewal fee patent year 04 | 29.01.2024 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2014044686 (INNATE PHARMA [FR]) [X] 3-19,21-27 * example 2 * * page 70, line 31 *; | [X]WO2018073363 (INNATE PHARMA [FR]) [X] 3-19,21-27 * sequences 31, 26, 25 *; | [A]US2018291102 (GAULARD PHILIPPE [FR], et al) [A] 35* paragraphs [0059] , [0066] , [0008] , [0090] , [0244] , [0261] , [0445] *; | [XI] - ARGNANI LISA ET AL, "Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease", CANCER TREATMENT REVIEWS, (20171028), vol. 61, doi:10.1016/J.CTRV.2017.10.007, ISSN 0305-7372, pages 61 - 69, XP085264458 [X] 3-19,27-32,34 * table 1 * * page 66, column right * * both columns; page 64 * [I] 1-17,19-28,30-34 DOI: http://dx.doi.org/10.1016/j.ctrv.2017.10.007 | [XI] - PRINCE H MILES ET AL, "Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome", BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, ELSEVIER, AMSTERDAM, NL, (20180718), vol. 31, no. 3, doi:10.1016/J.BEHA.2018.07.007, ISSN 1521-6926, pages 322 - 335, XP085470247 [X] 3-19,27-32,34 * pages 332, 332 * * paragraph [08.1] * [I] 1-17,19-28,30-34 DOI: http://dx.doi.org/10.1016/j.beha.2018.07.007 | [X] - JULIAN A. MARIN-ACEVEDO ET AL, "Next generation of immune checkpoint therapy in cancer: new developments and challenges", JOURNAL OF HEMATOLOGY & ONCOLOGY, (20180315), vol. 11, no. 1, doi:10.1186/s13045-018-0582-8, XP055642850 [X] 3-19,27 * bottom left; page 11 * DOI: http://dx.doi.org/10.1186/s13045-018-0582-8 | [X] - A. MARIE-CARDINE ET AL, "IPH4102, a Humanized KIR3DL2 Antibody with Potent Activity against Cutaneous T-cell Lymphoma", CANCER RESEARCH, US, (20141101), vol. 74, no. 21, doi:10.1158/0008-5472.CAN-14-1456, ISSN 0008-5472, pages 6060 - 6070, XP055437131 [X] 3-19,27 * the whole document * DOI: http://dx.doi.org/10.1158/0008-5472.CAN-14-1456 | [XI] - YAO YI-YUN ET AL, "Retrospective Study of Pegaspargase, Gemicitabine, Oxaliplatin and Dexamethasone (Peg-GemOD) as a First-Line Therapy for Advanced-Stage Extranodal NK/T Cell Lymphoma", INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, SPRINGER-VERLAG, INDIA, vol. 33, no. 1, doi:10.1007/S12288-016-0670-2, ISSN 0971-4502, (20160319), pages 74 - 81, (20160319), XP036145702 [X] 33 * abstract * [I] 1-17,19-28,30-34 DOI: http://dx.doi.org/10.1007/s12288-016-0670-2 | [IP] - M Cheminant ET AL, "157 KIR3DL2 IS EXPRESSED IN PERIPHERAL T-CELL LYMPHOMAS AND MAY BE A THERAPEUTIC TARGET", Hematological Oncology - Volume 37, Issue S2 Supplement: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano, Switzerland, 18-22 June, 2019, (20190612), pages 204 - 205, URL: https://onlinelibrary.wiley.com/doi/full/10.1002/hon.21_2630, (20200414), XP055685274 [IP] 1-35 * the whole document * | by applicant | US4816567 | US5660827 | WO0042072 | US6162963 | WO0250122 | WO2004032269 | US6737056 | WO2004063351 | WO2004099249 | US6821505 | WO2005047327 | WO2005110474 | WO2005115452 | WO2006088494 | US7122637 | WO2007021841 | US7183387 | WO2007024249 | WO2007106707 | WO2008002933 | US7332581 | US7335742 | US7355008 | US7371826 | US7416727 | WO2008105886 | US7425619 | US7521542 | US7632497 | WO2010081890 | WO2011109400 | WO2014044681 | WO2014044686 | WO2014128221 | - CHOTHIALESK, J. Mol. Biol, (19870000), vol. 196, pages 901 - 917 | - CARIL et al., SIAM J. Applied Math., (19880000), vol. 48, page 1073 | - WANG et al., Nature, (19920000), vol. 355, pages 275 - 278 | - MULLER, Meth. Enzymol., (19830000), vol. 92, pages 589 - 601 | - NICE et al., J. Chroma-togr., (19930000), vol. 646, pages 159 - 168 | - CHOTHIALESK, J. Mol., (19870000), vol. 196, page 901 | - DEVEREUX et al., Nucl. Acid. Res., (19840000), vol. 12, page 387 | - ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, pages 403 - 410 | - WILLEMZE et al., Blood, (20050000), vol. 105, pages 3768 - 3785 | - OLSEN et al., Blood, (20070000), vol. 110, no. 6, pages 1713 - 1722 | - AGAR et al., J. Clin. Oncol., (20100000), vol. 28, no. 31, pages 4730 - 4739 | - FOSS et al., Blood, (20110000), vol. 117, pages 6756 - 6767 | - PENDE et al., J. Exp. Med., (19960000), vol. 184, pages 505 - 518 | - "Genbank", Database accession no. AAB36593 | - COLONNASAMARIDIS, Science, (19950000), vol. 267, no. 5209, pages 383 - 386 | - REICHMANN et al., Nature, (19880000), vol. 332, page 323 | - JONES et al., Nature, (19860000), vol. 321, pages 522 - 103 | - WARD et al., Nature, (19890000), vol. 341, page 544 | - EHRING H, Analytical Biochemistry, (19990000), vol. 267, no. 2, pages 252 - 259 | - ENGEN, J. R.SMITH, D. L., Anal. Chem., (20010000), vol. 73, pages 256A - 265A | - Ernst Schering Res Found Workshop, (20040000), vol. 44, pages 149 - 67 | - HUANG et al., Journal of Molecular Biology, (19980000), vol. 281, no. 1, pages 61 - 67 | - SAITOPATTERSON, Methods, (19960600), vol. 9, no. 3, pages 516 - 24 | - DOWNARD, J Mass Spectrom, (20000400), vol. 35, no. 4, pages 493 - 503 | - KISELARDOWNARD, Anal Chem., (19990501), vol. 71, no. 9, pages 1792 - 1801 | - WELLS, Proc Natl Acad Sci USA, (19960000), vol. 93, pages 1 - 6 | - FAGERSTAM et al., Journal Of Molecular Recognition, (19900000), vol. 3, pages 208 - 14 | - LEIPERT et al., Angew. Chem. Int. Ed., (19980000), vol. 37, pages 3308 - 3311 | - KROGER et al., Biosensors and Bioelectronics, (20020000), vol. 17, pages 937 - 944 | - SKERRA et al., Curr. Opinion in Immunol., (19930000), vol. 5, page 256 | - PLUCKTHUN, Immunol., (19920000), vol. 130, page 151 | - MORRISON et al., PNAS, (19840000), page 6851 | - PRESTA, Curr. Op. Struct. Biol., (19920000), vol. 2, page 593 | - VERHOEYEN, Science, vol. 239, page 1534 | - PRESTA et al., J. Immunol., (19930000), vol. 151, page 2623 | - CARTER et al., PNAS, (19920000), vol. 89, page 4285 | - JAKOBOVITZ et al., Nature, (19930000), vol. 362, page 255 | - LAZAR et al., Proc. Nat. Acad. Sci. USA, (20060000), vol. 103, no. 11, pages 405 - 410 | - PRESTA, L.G. et al., Biochem. Soc. Trans., (20020000), vol. 30, no. 4, pages 487 - 490 | - SHIELDS, R.L. et al., J. Biol. Chem., (20020000), vol. 277, no. 30, pages 26733 - 26740 | - SHIELDS, R.L. et al., J. Biol. Chem., (20010000), vol. 276, no. 9, pages 6591 - 6604 | WO2013EP69302 | WO2013EP69293 |